Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity, and neutralization sensitivity.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
30 Nov 2023
Historique:
medline: 1 12 2023
pubmed: 20 10 2023
entrez: 20 10 2023
Statut: ppublish

Résumé

The Omicron subvariants have substantially evaded host-neutralizing antibodies and adopted an endosomal route of entry. The virus has acquired several mutations in the receptor binding domain and N-terminal domain of S1 subunit, but remarkably, also incorporated mutations in S2 which are fixed in Omicron sub-lineage. Here, we found that the mutations in the S2 subunit affect the structural and biological properties such as neutralization escape, entry route, fusogenicity, and protease requirement.

Identifiants

pubmed: 37861334
doi: 10.1128/jvi.00922-23
pmc: PMC10688319
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Endopeptidases EC 3.4.-
Peptide Hydrolases EC 3.4.-
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0092223

Subventions

Organisme : DST | Science and Engineering Research Board (SERB)
ID : IPA/2020/000168
Organisme : Council of Scientific and Industrial Research, India (CSIR)
Organisme : CSIR-Institute of Genomics and Integrative Biology
ID : MLP-2005
Organisme : Fondation Botnar (Botnar Foundation)
ID : CLP-0031

Déclaration de conflit d'intérêts

R.V. and R.S. are inventors on a patent application for RBD and Spike antigens used in this study; other authors declare no conflict of interest.

Références

Lancet. 2021 Dec 11;398(10317):2173-2184
pubmed: 34774196
Nature. 2020 Aug;584(7821):450-456
pubmed: 32698192
Nature. 2021 Sep;597(7874):103-108
pubmed: 34280951
Science. 2020 Aug 21;369(6506):956-963
pubmed: 32540903
Nature. 2022 Mar;603(7902):700-705
pubmed: 35104835
ACS Infect Dis. 2021 Aug 13;7(8):2546-2564
pubmed: 34260218
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Cell. 2021 Apr 29;184(9):2332-2347.e16
pubmed: 33761326
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5318-23
pubmed: 19289833
Annu Rev Med. 2022 Jan 27;73:1-16
pubmed: 34428080
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Elife. 2020 Oct 28;9:
pubmed: 33112236
Signal Transduct Target Ther. 2022 Apr 7;7(1):118
pubmed: 35393393
Cell. 2021 Apr 29;184(9):2372-2383.e9
pubmed: 33743213
Mol Cell. 2022 Jun 2;82(11):2050-2068.e6
pubmed: 35447081
Lancet Infect Dis. 2023 May;23(5):556-567
pubmed: 36681084
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Nature. 2020 Jul;583(7815):290-295
pubmed: 32422645
Cell. 2022 Jun 9;185(12):2103-2115.e19
pubmed: 35568035
Nat Commun. 2023 Jan 19;14(1):302
pubmed: 36653360
Science. 2021 Aug 6;373(6555):
pubmed: 34168071
Nat Commun. 2022 Feb 22;13(1):1002
pubmed: 35194049
Sci Transl Med. 2022 Mar 23;14(637):eabi9215
pubmed: 35133175
J Virol. 1993 Feb;67(2):933-42
pubmed: 7678310
Cell. 2021 Apr 29;184(9):2316-2331.e15
pubmed: 33773105
Cell Host Microbe. 2023 Jan 11;31(1):9-17.e3
pubmed: 36476380
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5
pubmed: 35120605
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
PLoS Pathog. 2021 Apr 8;17(4):e1009453
pubmed: 33831132
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Trends Microbiol. 2004 Oct;12(10):466-72
pubmed: 15381196
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
PLoS Pathog. 2022 Nov 18;18(11):e1010951
pubmed: 36399443
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Cell. 2022 Mar 3;185(5):860-871.e13
pubmed: 35120603
Cell. 2021 Apr 15;184(8):2183-2200.e22
pubmed: 33756110
Cell Host Microbe. 2021 May 12;29(5):819-833.e7
pubmed: 33789084
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
iScience. 2023 Feb 17;26(2):105981
pubmed: 36694788
N Engl J Med. 2021 Sep 30;385(14):1330-1332
pubmed: 34469645
Nat Commun. 2022 Nov 16;13(1):7011
pubmed: 36384919
J Virol. 2022 Jul 13;96(13):e0047422
pubmed: 35678602
Commun Biol. 2022 Apr 11;5(1):342
pubmed: 35411021
N Engl J Med. 2021 Dec 16;385(25):e92
pubmed: 34758250
Science. 2022 Feb 18;375(6582):760-764
pubmed: 35050643
Cell. 2022 Oct 13;185(21):3992-4007.e16
pubmed: 36198317
Nat Commun. 2023 Jun 13;14(1):3500
pubmed: 37311762
Cell. 2021 Apr 29;184(9):2348-2361.e6
pubmed: 33730597
Immunity. 2021 Aug 10;54(8):1636-1651
pubmed: 34348117
Nature. 2022 Mar;603(7903):913-918
pubmed: 35114688
Nature. 2021 Dec;600(7889):512-516
pubmed: 34544114
Mayo Clin Proc. 2022 Dec;97(12):2324-2332
pubmed: 36464465
Nature. 2020 Aug;584(7821):443-449
pubmed: 32668443
Nature. 2020 Dec;588(7837):327-330
pubmed: 32942285
Nat Struct Mol Biol. 2020 Oct;27(10):925-933
pubmed: 32699321
Proc Natl Acad Sci U S A. 2022 Jan 4;119(1):
pubmed: 34930824
iScience. 2022 Dec 22;25(12):105720
pubmed: 36507224
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Nat Med. 2023 Feb;29(2):344-347
pubmed: 36473500
Cell Rep. 2022 Jun 14;39(11):110924
pubmed: 35658975
EClinicalMedicine. 2021 Dec;42:101218
pubmed: 34870133
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
JAMA. 2021 Mar 2;325(9):821-822
pubmed: 33507218
Science. 2020 Aug 7;369(6504):643-650
pubmed: 32540902
Signal Transduct Target Ther. 2022 Apr 28;7(1):141
pubmed: 35484110
Front Immunol. 2021 Dec 09;12:765211
pubmed: 34956193
Nature. 2021 Jul;595(7867):426-431
pubmed: 34126625
Nat Microbiol. 2022 Oct;7(10):1709
pubmed: 36114232
Nature. 2021 May;593(7857):130-135
pubmed: 33684923

Auteurs

Sahil Kumar (S)

CSIR-Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR) , Chandigarh, India.

Rathina Delipan (R)

CSIR-Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR) , Chandigarh, India.

Debajyoti Chakraborty (D)

Molecular Biophysics Unit (MBU), Indian Institute of Science , Bangalore, India.

Kawkab Kanjo (K)

Molecular Biophysics Unit (MBU), Indian Institute of Science , Bangalore, India.

Randhir Singh (R)

Mynvax Pvt. Ltd. , Bangalore, India.

Nittu Singh (N)

CSIR-Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR) , Chandigarh, India.

Samreen Siddiqui (S)

Max Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare , Delhi, India.

Akansha Tyagi (A)

Max Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare , Delhi, India.

Vinitaa Jha (V)

Max Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare , Delhi, India.

Krishan G Thakur (KG)

CSIR-Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR) , Chandigarh, India.

Rajesh Pandey (R)

CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB) , Delhi, India.

Raghavan Varadarajan (R)

Molecular Biophysics Unit (MBU), Indian Institute of Science , Bangalore, India.

Rajesh P Ringe (RP)

CSIR-Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR) , Chandigarh, India.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH